Literature DB >> 10204841

Evaluation of a mutation screening strategy for sporadic cases of ATR-X syndrome.

L Villard1, M C Bonino, F Abidi, A Ragusa, J Belougne, A M Lossi, L Seaver, J P Bonnefont, C Romano, M Fichera, D Lacombe, A Hanauer, N Philip, C Schwartz, M Fontés.   

Abstract

We report on the evaluation of a strategy for screening for XNP/ATR-X mutations in males with mental retardation and associated dysmorphology. Because nearly half of the mutations in this gene reported to date fall into a short 300 bp region of the transcript, we decided to focus in this region and to extend the mutation analysis to cases with a negative family history. This study includes 21 mentally retarded male patients selected because they had severe mental retardation and a typical facial appearance. The presence of haemoglobin H or urogenital abnormalities was not considered critical for inclusion in this study. We have identified six mutations which represents a mutation detection rate of 28%. This figure is high enough for us to propose this strategy as a valid first level of screening in a selected subset of males with mental retardation. This approach is simple, does not require RNA preparation, does not involve time consuming mutation detection methods, and can thus be applied to a large number of patients at a low cost in any given laboratory.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204841      PMCID: PMC1734331     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  8 in total

1.  A point mutation in the XNP gene, associated with an ATR-X phenotype without alpha-thalassemia.

Authors:  L Villard; D Lacombe; M Fontés
Journal:  Eur J Hum Genet       Date:  1996       Impact factor: 4.246

2.  XNP mutation in a large family with Juberg-Marsidi syndrome.

Authors:  L Villard; J Gecz; J F Mattéi; M Fontés; P Saugier-Veber; A Munnich; S Lyonnet
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

3.  Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain.

Authors:  R J Gibbons; S Bachoo; D J Picketts; S Aftimos; B Asenbauer; J Bergoffen; S A Berry; N Dahl; A Fryer; K Keppler; K Kurosawa; M L Levin; M Masuno; G Neri; M E Pierpont; S F Slaney; D R Higgs
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

4.  Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without alpha-thalassemia.

Authors:  L Villard; A Toutain; A M Lossi; J Gecz; C Houdayer; C Moraine; M Fontès
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

5.  Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).

Authors:  R J Gibbons; D J Picketts; L Villard; D R Higgs
Journal:  Cell       Date:  1995-03-24       Impact factor: 41.582

Review 6.  Clinical and hematologic aspects of the X-linked alpha-thalassemia/mental retardation syndrome (ATR-X).

Authors:  R J Gibbons; L Brueton; V J Buckle; J Burn; J Clayton-Smith; B C Davison; R J Gardner; T Homfray; L Kearney; H M Kingston
Journal:  Am J Med Genet       Date:  1995-01-30

7.  Determination of the genomic structure of the XNP/ATRX gene encoding a potential zinc finger helicase.

Authors:  L Villard; A M Lossi; C Cardoso; V Proud; P Chiaroni; L Colleaux; C Schwartz; M Fontés
Journal:  Genomics       Date:  1997-07-15       Impact factor: 5.736

8.  X-linked alpha-thalassemia/mental retardation (ATR-X) syndrome: localization to Xq12-q21.31 by X inactivation and linkage analysis.

Authors:  R J Gibbons; G K Suthers; A O Wilkie; V J Buckle; D R Higgs
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

  8 in total
  6 in total

1.  ATR-X mutations cause impaired nuclear location and altered DNA binding properties of the XNP/ATR-X protein.

Authors:  C Cardoso; Y Lutz; C Mignon; E Compe; D Depetris; M G Mattei; M Fontes; L Colleaux
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

Review 2.  Fragile X and X-linked intellectual disability: four decades of discovery.

Authors:  Herbert A Lubs; Roger E Stevenson; Charles E Schwartz
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

3.  Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain.

Authors:  Norifumi Shioda; Hideyuki Beppu; Takaichi Fukuda; En Li; Isao Kitajima; Kohji Fukunaga
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

4.  SA4503, A Potent Sigma-1 Receptor Ligand, Ameliorates Synaptic Abnormalities and Cognitive Dysfunction in a Mouse Model of ATR-X Syndrome.

Authors:  Kouya Yamaguchi; Norifumi Shioda; Yasushi Yabuki; Chen Zhang; Feng Han; Kohji Fukunaga
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

5.  Identification of a Hemizygous Novel Splicing Variant in ATRX Gene: A Case Report and Literature Review.

Authors:  Yan Cong; Jie Wu; Hao Wang; Ke Wu; Cui Huang; Xuejian Yang
Journal:  Front Pediatr       Date:  2022-04-04       Impact factor: 3.418

Review 6.  The Multiple Facets of ATRX Protein.

Authors:  Martina Valenzuela; Roberta Amato; Antonella Sgura; Antonio Antoccia; Francesco Berardinelli
Journal:  Cancers (Basel)       Date:  2021-05-05       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.